Bitcoin’s success reflects a growing shift in how the world approaches not only cryptocurrency but also financial markets as ...

The fast-food chain argues in a counterclaim against Paradigm Investment Group that the operator is the only traditional ...

RBI's big beautiful monetary policy, rising market activity a cause for concern, global growth slows but markets are soaring, ...

When a retailer offers a chatbot to communicate with customers and solve their queries, or when a bank sends an SMS for ...

A new gene risk score, informed by machine learning, can predict weight-loss outcomes after Roux-en-Y gastric bypass surgery.

Vineeth Gogineni is a Manager at Bain & Company, based in the Dallas office, serving private and public sector clients across ...

How Rick Carter, producer designer of blockbusters for Steven Spielberg and Jim Cameron, sees GenAI emerging as a ...

Axsome Therapeutics (AXSM) shares drop after FDA declines review of fibromyalgia treatment AXS-14. Read more here.

Long-term maintenance with P2Y12 inhibitor monotherapy after discontinuing dual antiplatelet therapy (DAPT) in patients ...

And the narrative here is that Los Angeles is in complete chaos as a result of Donald Trump attempting to enforce federal law ...

Investing.com -- Shares of Axsome Therapeutics Inc (NASDAQ: AXSM) fell 1.2% following the U.S. Food and Drug Administration’s (FDA) Refusal to File (RTF) letter regarding the company’s New Drug ...

Axsome Therapeutics received a refusal-to-file letter from the Food and Drug Administration for its new drug application for its fibromyalgia drug AXS-14.